SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+58.64%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.79B
AUM Growth
+$1.79B
(+24%)
Cap. Flow
-$228M
Cap. Flow
% of AUM
-12.79%
Top 10 Holdings %
Top 10 Hldgs %
65.35%
Holding
73
New
17
Increased
15
Reduced
16
Closed
9
Top Buys
| 1 |
Eli Lilly
LLY
|
$37.6M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$33.3M |
| 3 |
Kura Oncology
KURA
|
$24M |
| 4 |
Incyte
INCY
|
$18.6M |
| 5 |
Stryker
SYK
|
$17.8M |
Top Sells
| 1 |
Natera
NTRA
|
$97.1M |
| 2 |
DexCom
DXCM
|
$65.8M |
| 3 |
Cytokinetics
CYTK
|
$53.9M |
| 4 |
Elanco Animal Health
ELAN
|
$36M |
| 5 |
AstraZeneca
AZN
|
$34.5M |
Sector Composition
| 1 | Healthcare | 97.37% |
| 2 | Consumer Staples | 1.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
INZY
26
DELISTED
Inozyme Pharma
INZY
| $18.2M | 1.02% |
4,280,308
| – | – |
|
|
27
Elanco Animal Health
ELAN
$8.62B
| $17.8M | 1% |
1,193,885
-2,416,139
| -67% | -$36M |
|
28
argenx
ARGX
$44.2B
| $17M | 0.95% |
44,721
-33,465
| -43% | -$12.7M |
|
29
Y-mAbs Therapeutics
YMAB
$390M
| $15M | 0.84% |
2,194,278
| – | – |
|
30
Pharvaris
PHVS
$1.41B
| $14.3M | 0.8% |
+510,441
| New | +$14.3M |
|
31
Dyne Therapeutics
DYN
$1.92B
| $13.5M | 0.75% |
1,013,505
+328,372
| +48% | +$4.37M |
|
|
AGEN
32
Agenus
AGEN
$136M
| $13M | 0.73% |
15,656,234
+2,291,486
| +17% | +$1.9M |
|
33
Savara
SVRA
$591M
| $11.2M | 0.63% |
2,382,835
+2,224,927
| +1,409% | +$10.5M |
|
34
Mirum Pharmaceuticals
MIRM
$3.75B
| $10.4M | 0.58% |
352,397
+343,308
| +3,777% | +$10.1M |
|
35
Cabaletta Bio
CABA
$144M
| $9.75M | 0.55% |
+429,395
| New | +$9.75M |
|
36
Immunovant
IMVT
$2.91B
| $9.38M | 0.52% |
222,553
+82,668
| +59% | +$3.48M |
|
37
Boston Scientific
BSX
$159B
| $7.57M | 0.42% |
+131,000
| New | +$7.57M |
|
38
Structure Therapeutics
GPCR
$1.14B
| $7.13M | 0.4% |
174,838
-27,281
| -13% | -$1.11M |
|
39
MoonLake Immunotherapeutics
MLTX
$3.78B
| $6.87M | 0.38% |
113,757
-179,048
| -61% | -$10.8M |
|
40
Insulet
PODD
$24.2B
| $4.12M | 0.23% |
+19,000
| New | +$4.12M |
|
41
Ironwood Pharmaceuticals
IRWD
$201M
| $3.79M | 0.21% |
+331,099
| New | +$3.79M |
|
42
Bolt Biotherapeutics
BOLT
$9.29M
| $3.08M | 0.17% |
2,754,437
| – | – |
|
43
NextCure
NXTC
$13.3M
| $3.05M | 0.17% |
2,671,856
| – | – |
|
|
44
DexCom
DXCM
$30.9B
| $2.48M | 0.14% |
20,000
-530,197
| -96% | -$65.8M |
|
45
Cooper Companies
COO
$13.3B
| $1.51M | 0.08% |
+4,000
| New | +$1.51M |
|
46
Masimo
MASI
$7.43B
| $1.5M | 0.08% |
+12,800
| New | +$1.5M |
|
|
NCNA
47
NuCana
NCNA
$5.8M
| $1.39M | 0.08% |
4,684,120
-915,879
| -16% | -$271K |
|
|
FUSN
48
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $1.2M | 0.07% |
125,299
+8,200
| +7% | +$78.8K |
|
|
IMTXW
49
DELISTED
Immatics N.V. Warrants
IMTXW
| $930K | 0.05% |
318,372
-524
| -0.2% | -$1.53K |
|
|
IMA
50
ImageneBio, Inc. Common Stock
IMA
$153M
| $716K | 0.04% |
363,479
+247,767
| +214% | +$488K |
|